Super Studienergebnisse gegen Krebs in Phase 2!
Seite 1 von 3 Neuester Beitrag: 31.12.21 00:59 | ||||
| Eröffnet am: | 19.09.15 11:49 | von: der inder | Anzahl Beiträge: | 61 |
| Neuester Beitrag: | 31.12.21 00:59 | von: Balu4u | Leser gesamt: | 21.051 |
| Forum: | Hot-Stocks | Leser heute: | 6 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | 3 > | ||||
According to the trial:
Beta human chorionic gonadotropin (β-hCG), a known, reliable marker of disease burden in choriocarcinoma, normalized during the fourth cycle of treatment, decreasing from greater than 3,000 IU/L at treatment initiation to less than 1 IU/L from cycles 4 through 7, indicating an ongoing complete response.
http://finance.yahoo.com/news/...surges-positive-study-130522738.html
Die Bude ist gerade mal mit 200 Mill USD an der Börse bewertet und hat noch 60 Mill USD Cash und hat das Protein das Krebs heilt in der Pipeline.
Strong buy = I like
Optionen
| Boardmail an "Rudini" |
Wertpapier: Tracon Pharmaceuticals |
https://www.chartmill.com/stock/quote/TCON/...ampaign=social_tracking
Optionen
| Boardmail an "Küstennebel" |
Wertpapier: Tracon Pharmaceuticals |
Angehängte Grafik:
44.jpg (verkleinert auf 41%)
44.jpg (verkleinert auf 41%)
https://www.globenewswire.com/news-release/2020/...ruary-27-2020.html
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Tracon Pharmaceuticals |
MFG
Chali
Optionen
| Boardmail an "Chalifmann3" |
Wertpapier: Tracon Pharmaceuticals |
Das hier hab ich gefunden,ich glaube eure Tracon ist ne fette Niete,ich würde aussteigen Balu :
Tracon Pharmaceuticals has terminated the Phase III TAPPAS clinical trial conducted to assess TRC105 plus Votrient (pazopanib) in advanced or metastatic angiosarcoma patients.
The move comes after a review by the Independent Data Monitoring Committee (IDMC) found that the combination did not lead to clinically meaningful efficacy.
The IDMC analysed interim unblinded safety and efficacy findings from more than 120 participants.
TRC105 is an oncology formulation of carotuximab and an antibody to the endoglin protein, which is overexpressed on proliferating endothelial cells required for the formation of new blood vessels.
“We are disappointed that TRC105 in combination with Votrient did not demonstrate clinically meaningful efficacy.”
TAPPAS was intended to evaluate TRC105 in combination with Votrient, compared to Votrient alone, in a total of 340 subjects. Tracon started dosing patients in the trial in February 2017.
The trial’s primary endpoint was progression-free survival. Its secondary endpoints included objective response rate, safety, overall survival, and tolerability.
Based on the TAPPAS results, the company has decided to terminate further enrolment into its trials of TRC105 in oncology indications.
Optionen
| Boardmail an "Chalifmann3" |
Wertpapier: Tracon Pharmaceuticals |
Ich glaube in Germany hat das Teil hier kaum einer aufm Schirm! 
Bin selber schon sehr gut im Plus!
Optionen
| Boardmail an "Küstennebel" |
Wertpapier: Tracon Pharmaceuticals |
https://www.investorsobserver.com/news/...on-stock-buy-hold-or-sell-3
Optionen
| Boardmail an "Küstennebel" |
Wertpapier: Tracon Pharmaceuticals |
https://old.nasdaq.com/de/symbol/tcon/real-time
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Tracon Pharmaceuticals |
Optionen
| Boardmail an "Küstennebel" |
Wertpapier: Tracon Pharmaceuticals |
Optionen
| Boardmail an "Küstennebel" |
Wertpapier: Tracon Pharmaceuticals |
Optionen
| Boardmail an "Küstennebel" |
Wertpapier: Tracon Pharmaceuticals |
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Tracon Pharmaceuticals |
In a report released yesterday, Robert Hazlett from BTIG maintained a Buy rating on TRACON Pharmaceuticals, with a price target of $14.00. The companys shares closed last Monday at $2.91, close to its 52-week low of $2.18.
https://www.analystratings.com/articles/...acon-pharmaceuticals-tcon/
Optionen
| Boardmail an "Balu4u" |
Wertpapier: Tracon Pharmaceuticals |